The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity

Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2003, Pages 34-48

  Hanessian, Stephen ^a   Parthasarathy, Saravanan ^a   Mauduit, Marc ^a   Payza, Kemal ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; AROMATIC COMPOUND; AZOCINE DERIVATIVE; DEXTRO ALANINE; DEXTRO AMINO ACID; ISOPAVINE; MORPHINOMIMETIC AGENT; MU OPIATE RECEPTOR AGONIST; N METHYL (3,8 BISBENZYLAMINO) 6 METHYLISOPAVINE; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; STEREOCHEMISTRY; STEVENS REACTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

AZOCINES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; MORPHINE DERIVATIVES; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; STEREOISOMERISM;

EID: 0037413546     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020164l     Document Type: Article

References (72)

1. Belleau, B. R. The curse of opium: Requital through organic medicinal chemistry. Chem. Can. 1980, 24-25.
2. Rice, K. C. Natural and unnatural codeine, morphine analogs. In The Chemistry and Biology of Isoquinoline Alkaloids; Phillipson, J. D., Roberts, M. F., Zenk, M., Eds.: Springer-Verlag: Berlin, 1985; pp 191-203.
3. Szàntay, C.; Dörnyei, G.; Blaskó, G. The morphine alkaloids. In The Alkaloids; Cordell, G. A., Brossi, A., Eds.; Academic: New York, 1994, 45, 127-232.
4. Schiller, P. W. In Progress in Medicinal Chemistry; Ellis, G. P., West, G. B., Eds.; North Holland: Amsterdam, 1991; Vol. 28, pp 301-340.
5. Dhawan, B. N.; Cesselin, F.; Raghubir, R.; Reisine, T.; Bradley, P. B.; Portoghese, P. S.; Hamon, M. International union of pharmacology. XII. Classification of opioid receptors. Pharma. Col. Rev. 1996, 48, 567-592.
6. Gether, U. Uncovering molecular mechanisms involved in activation of G-protein coupled receptors. Endocr. Rev. 2000, 21, 90-113.
7. Alkorta, I.; Lowe, G. H. A 3D model of the δ opioid receptor and ligand-receptor complex. Protein Eng. 1996, 9, 573-583.
8. Strahs, D.; Weinstein, H. Comparative modeling and molecular dynamics studies of the δ, κ, and μ opioid receptors. Protein Eng. 1997, 10, 1019-1038.
9. Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys. J. 1998, 75, 612-634.
10. Filizola, M.; Carteni-Farina, M.; Perez, J. J. Molecular modeling study of the differential ligand-receptor interaction at the μ, δ and κ opioid receptors. J. Comput.-Aided Mol. Des. 1999, 13, 397-407.
11. Zhorov, B, S.; Ananthanarayanan, V. S. Homology models of μ-opioid receptors with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains. Arch. Biochem. Biophys. 2000, 375, 31-49.
12. Reisine, T. Opiate receptors. Neuropharmacology 1995, 34, 463-472.
13. Zaki, P. A.; Bilsky, T. W.; Vanderah, T. W.; Lai, J.; Evans, C. J.; Porreca, F. Opioid receptor types and subtypes: The δ-receptor as a model. Annu. Rev. Pharmacol. Toxicol. 1996, 36, 379-401.
14. Filizola, M.; Villar, H. O.; Loew, G. H. Molecular determinants of non-specific recognition of δ, μ and κ opioid receptors. Bioorg. Med. Chem. 2001, 9, 69-76.
15. Fürst, S.; Hosztafi, S.; Friedman, T. Structure-activity relationships of synthetic and semisynthetic opioid agonists and antagonists. Curr. Med. Chem. 1995, 1, 423-440.
16. Aldrich, J. V. Analgesics. In Burger's Medicinal Chemistry and Drug Discovery; Wolff, M. E., Ed.; John Wiley & Sons: New York, 1996; Vol. 3, pp 321-441.
17. Fournie-Zaluski, M.-C.; Gacel, G.; Maigret, B.; Premilat, S.; Roques, B. P. Structural requirements for specific recognition of μ or δ opiate receptors. Mol. Pharmacol. 1981, 20, 484-491.
18. Portoghese, P. S. A new concept on the mode of interaction of narcotic analgesics with receptors. J. Med. Chem. 1965, 8, 609-616.
19. Beckett, A. H.; Casy, A. F. Synthetic analgesics: Stereochemical considerations. J. Pharma: Pharmacol. 1954, 6, 986-1001.
20. Schultz, A. G.; Wang, A.; Alva, C.; Sebastian, A.; Glick, S. D.; Deecher, D. C.; Bidlack, J. M. Asymmetric synthesis, opioid receptor affinities, and antinociceptive effects of 8-amino-5,9-methanobenzo cyclooctenes, a new class of structural analogues of the morphine alkaloids. J. Med. Chem. 1996, 39, 1956-1966.
21. Wentland, M. P.; Duan, W.; Cohen, D. J.; Bidlack, J. M. Selective protection and functionalization of morphine: Synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives. J. Med. Chem. 2000, 43, 3558-3565.
22. Davies, S. G.; Goodwin, C. J.; Pyatt, D.; Smith, A. D. Palladium catalyzed elaboration of codeine and morphine. J. Chem. Soc., Perkin Trans. 1 2001, 1412-1420.
23. Derrick, I.; Neilan, C. L.; Amdes, J.; Husbands, S.; Woods, J. H.; Traynor, J. R.; Lewis, J. W. 3-Deoxycyclocinnamox: The first high-affinity, nonpeptide μ-opioid antagonist lacking a phenolic hydroxyl group. J. Med. Chem. 2000, 43, 3348-3350.
24. Hruby, V. J.; Gehrig, C. A. Recent developments in the design of receptor specific opioid peptides. Med. Res. Rev. 1989, 9, 343-401.
25. Schiller, P. W.; Berezowska, I.; Nguyen, T. M.-D.; Schmidt, R.; Lemieux, C.; Chung, N. N.; Falcone-Hindley, M. L.; Yao, W.; Liu, J.; Iwama, S.; Smith, A. B., III; Hirschmann, R. Novel ligands lacking a positive charge for the δ- and μ-opioid receptors. J. Med. Chem. 2000, 43, 551-559.
26. Pagé, D.; Naismith, A.; Schmidt, R.; Coupal, M.; Labarre, M.; Gosselin, M.; Bellemare, D.; Payza, K.; Brown, W. Novel C-Terminus. Modifications of the Dmt-Tic Motif: A New Class of Dipeptide Analogues Showing Altered Pharmacological Profiles toward the Opioid Receptors. J. Med. Chem. 2001, 44, 2387-2390.
27. Kumar, V.; Marello, M. A.; Cortes-Burgos, L.; Chang, A.-C.; Cassel, J. A.; Daubert, J. D.; DeHaven, R. N.; DeHaven-Hudkins, D. L.; Gottshall, S. L.; Mansson, E.; Maycock, A. L. Arylacetamides as peripherally restricted kappa opioid receptor agonists. Bioorg. Med. Chem. Lett. 2000, 10, 2567-2570.
28. Law, P. Y.; Loh, H. H. Regulation of opioid receptor activities. J. Pharmacol. Exp. Ther. 1999, 289, 607-624.
29. Harrison, L. M.; Kastin, A. J.; Zadina, J. E. Opiate tolerance and dependence: Receptors, G-proteins, and antiopiates. Peptides 1998, 9, 1603-1630.
30. Massotte, D.; Keiffer, B. L. A molecular basis for opiate action. Essays Biochem. 1998, 33, 65-77.
31. Rees, D. C.; Hunter, J. C. Opioid receptors. In Comprehensive Medicinal Chemistry; Emmet, J. D., Ed.; Pergamon Press: New York, 1990; pp 805-846.
32. Monkovic, I.; Wong, H.; Pircio, A. W.; Perron, Y. G.; Pachter, I. J.; Belleau, B. Oxilorphan and butorphamol. Potent narcotic antagonists and nonaddicting analgesics in the 3,14-dihydroxymorphinan series. Part V. Can. J. Chem. 1975, 53, 3094-3102.
33. Archer, S.; Glick, S. D.; Bidlack, J. M. Cyclazocine revisited. Neurochem. Res. 1996, 21, 1369-1373.
34. Fink, M.; Freedman, A. M.; Resnick, R.; Zaks, A. In Agonist and Antagonist Actions of Narcotic Analgesic Drugs; Kosterlitz, H. W., Collier, H. O. J., Villareal, J. G., Eds.; Macmillan: New York, 1971; pp 266-276.
35. Wentland, M. P.; Xu, G.; Cioffi, C. L.; Ye, Y.; Duan, W.; Cohen, D. J.; Colasurdo, A. M.; Bidlack, J. M. 8-Aminocylclazocine analogues: Synthesis and structure activity relationships. Bioorg. Med. Chem. Lett. 2000, 10, 183-187.
36. Hughes, J.; Smith, T. N.; Kosterlitz, H. W.; Fotthergill, L. A.; Morgen, B. A.; Morris, H. R. Identification of two pentapeptides from brain with potent opiate agonist activity. Nature 1976, 258, 577-579.
37. Eddy, N. B.; May, E. L. The search for a better analgesic. Science 1973, 181, 407-414.
38. Maeda, D. Y.; Ishmael, J. E.; Murray, T. F.; Aldrich, J. V. Synthesis and evaluation of N,N-Dialkyl enkephalin-based affinity labels for δ opioid receptors. J. Med. Chem. 2000, 43, 3941-3948.
39. Jordan, B. A.; Cvejic, S.; Devi, L. A. Opioids and their complicated receptor complexes. Neuropsychopharmacology 2000, 23, S5-S18.
40. Schwyzer, R. ACTH: A short introductory review. Ann. N.Y. Acad. Sci. 1977, 247, 3-26.
41. Metzger, T. G.; Paterlini, M. G.; Portoghese, P. S.; Ferguson, D. M. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Neurochem. Res. 1996, 21, 1287-1294.
42. Portoghese, P. S. From models to molecules: Opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J. Med. Chem. 2001, 44, 2259-2269.
43. Takemori, A. E.; Portoghese, P. S. Selective naltrexone-derived opioid receptor antagonists. Annu. Rev. Pharmacol. Toxicol. 1992, 32, 239-269.
44. Lin, C. E.; Takemori, A. E.; Portoghese, P. S. Synthesis and κ-opioid antagonist selectivity of a norbinaltrophimine congener. Identification of the address moiety required for κ-antagonist activity. J. Med. Chem. 1993, 36, 2412-2415.
45. Portoghese, P. S.; Lin, C.-E.; Farouz-Grant, F.; Takemori, A. E. Structure-activity relationship of N17′-substituted norbinaltorphimine congeners. Role of the N17′ basic group in the interaction with a putative address substite on the ′-opioid receptor. J. Med. Chem. 1994, 37, 1495-1500.
46. Bolognesi, M. L.; Ojala, W. H.; Gleason, W. B.; Griffin, J. F.; Farouz-Grant, F.; Larson, D. L.; Takemori, A. E.; Portoghese, P. S. Opioid antagonist activity of naltrexone-derived bivalent ligands: Importance of a properly oriented molecular scaffold to guide "address" recognition at ′ opioid receptors. J. Med. Chem. 1996, 39, 1816-1822.
47. Belleau, B.; Conway, T.; Ahmed, F. R.; Hardy, A. D. Importance of the nitrogen lone electron pair orientation in stereospecific opiates. J. Med. Chem. 1974, 17, 907-908.
48. Belleau, B. Stereoelectronic regulation of the opiate receptor: Some conceptual problems. In Chemical Regulation of Biological Mechanisms; Burlington House, London, 1982; pp 201-221.
49. Hanessian, S.; Franco, J.; Larouche, B. The psychobiological basis of heuristic synthesis planning-man, machine and the Chiron approach. Pure Appl. Chem. 1990, 62, 1887-1910.
50. Hoffmann, R. The Same and Not the Same; Columbia University Press: New York, 1995.
51. Hanessian, S.; Mauduit, M. Highly diastereoselective intramolecular [1,2]-stevens rearrangements-asymmetric syntheses of functionalized isopavines as morphinomimetics. Angew. Chem., Int. Ed. 2001, 40, 3810-3813.
52. Hanessian, S.; Mauduit, M.; Demont, E.; Talbot, C. Synthesis of desymmetrized, enantiopure dihydro-methano-diarylazocines-topologically interesting eyeteaser molecules. Tetrahedron 2002, 58, 485-490.
53. Gözler, B. Pavine and isopavine alkaloids. In The Alkaloids; Academic Press: New York, 1987; Vol. 31, pp 317-389.
54. Markó, I. E. The stevens and related rearrangements. In Comprehensive Organic Synthesis; Trost, B. M., Fleming, I., Pattenden, I., Eds.; Pergamon: New York, 1991; Vol. 3, pp 913-973.
55. Stevens, T. S.; Creighton, E. M.; Gordon, A. B.; Macnicol, M. Degradation of Quaternary Ammonium Salts Part I. J. Chem. Soc. 1928, 3193-3197.
56. Laib, T.; Chastanet, J.; Zhu, J. Diastereoselective synthesis of γ-hydroxy-β-amino alcohols and (2S,3S)-β-hydroxyleucine from chiral D-(N,N-dibenzylamino)serine (TBDMS) aldehyde. J. Org. Chem. 1998, 63, 1709-1713.
57. Bobbitt, J. M.; Shibuya, S. Synthesis of isoquinolines. XI. Dibenzo [c,f]-1-azabicyclo[3.3.1]nonanes and 4-Phenyl-1,2,3,4-tetrahydroisoquinolines. J. Org. Chem. 1970, 35, 1181-1183.
58. Takayama, H.; Takamoto, M.; Okamoto, T. A General Synthesis of Dibenz[c,f]-1-aza-bicyclo[3.3.1]-nonane and Its Related Compounds. Tetrahedron Lett. 1978, 1307-1308.
59. Casadio, S.; Pala, G.; Crescenzi, E.; Marazzi-Uberti, E.; Coppi, G.; Turba, C. Synthesis and pharmacological properties of N-derivatives of 5,6-dihydro-7H,12H-dibenz[c,f]azocine, a new tricyclic system. J. Med. Chem. 1968, 11, 97-100.
60. Takayama, H.; Nomoto, T.; Suzuki, T.; Takamoto, M.; Okamoto, T. Base-induced reactions of N-methyl quaternary salts of 1-Aza-dibenzo[c,f]bicyclo[3.3.1]nona-3,6-diene and related compounds. Heterocycles 1978, 9, 1545-1548.
61. 1A receptor interactions. J. Med. Chem. 1995, 38, 647-658.
62. Wolfe, J. P.; Wagan, S.; Buchwald, S. L. An improved catalyst system for aromartic carbon-nitrogen bond formation: The possible involvement of Bis(phosphine)palladium complexes as key intermediates. J. Am. Chem. Soc. 1996, 118, 7215-7216.
63. Chaudhuri, N. K.; Servando, O.; Markus, B.; Galynker, I.; Sung, M. S. Catalytic N-dealkylation of tertiary amines: A biomimetic oxygenation reaction. J. Indian Chem. Soc. Soc. 1985, 62, 899-903.
64. Dyke, S. F.; Kinsman, R. G.; Warner, P.; White, A. W. C. Pavinane and isopavinane alkaloids. Correlation of absolute configurations by synthesis. Tetrahedron 1978, 34, 241-245.
65. Meyers, A. I.; Dickman, D. A.; Boes, M. Asymmetric synthesis of isoquinoline alkaloids. Tetrahedron 1987, 43, 5095-5108.
66. Canillo, L.; Badiá, D.; Dominguez, E.; Vicario, J. L.; Tellitu, I. A Simple and Efficient Synthetic Route to Chiral Isopavines. Synthesis of (-)-O-Methylthalisopavine and (-)-Amurensinine. J. Org. Chem. 1997, 62, 6716-6712,
67. Elliott, I. W., Jr. Synthesis of an isopavine alkaloid. (±)-O-Methylthalisopavine. J. Org. Chem. 1979, 44, 1162-1163.
68. Ollis, W. D.; Rey, M.; Sutherland, I. O. Base catalyzed rearrangements involving ylid intermediates. Part 15. The mechanism of the stevens [1,2] rearrangement. J. Chem. Soc., Perkin Trans. 1 1983, 1009-1027.
69. Wei, Z.-H.; Brown, W.; Takasaki, B.; Plobeck, N.; Delorme, D.; Zhou, F.; Yang, H.; Jones, P.; Gawell, L.; Gagnon, H.; Schmidt, R.; Yue, S.-Y.; Walpole, C.; Payza, K.; St-Onge, S.; Labarre, M.; Godbout, C.; Jakob, A.; Butterworth, J.; Kamassab, A.; Morin, P.-E.; Projean, D.; Ducharme, J.; Roberts, E. N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide; A novel exceptionally selective potent δ opioid receptor agonist with oral biovailability and its analogues. J. Med. Chem. 2000, 43, 3895-3905.
70. Andrews, P. Trends Pharmacol. Sci. 1986, 148-151.
71. Reiden, J.; Reich, M. F. Rice, K. C.; Jacobson, A. E.; Brossi, A. Deoxymorphines: Role of the phenolic hydroxyl group in the antinociceptive and opiate receptor interactions. J. Med. Chem. 1979, 22, 256-259.
72. Chen, Z. R.; Irvine, R. J.; Somogyi, A. A.; Bochner, F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci. 1991, 48, 2165-2171.